Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Amortization of Deferred Charges (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Amortization of Deferred Charges for 6 consecutive years, with $69000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortization of Deferred Charges fell 8.0% year-over-year to $69000.0, compared with a TTM value of $292000.0 through Dec 2025, down 2.01%, and an annual FY2025 reading of $292000.0, down 2.01% over the prior year.
  • Amortization of Deferred Charges was $69000.0 for Q4 2025 at Treace Medical Concepts, down from $75000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $75000.0 in Q4 2022 and bottomed at $43000.0 in Q1 2021.
  • Average Amortization of Deferred Charges over 5 years is $65350.0, with a median of $74000.0 recorded in 2022.
  • The sharpest move saw Amortization of Deferred Charges plummeted 33.85% in 2021, then skyrocketed 74.42% in 2022.
  • Year by year, Amortization of Deferred Charges stood at $43000.0 in 2021, then surged by 74.42% to $75000.0 in 2022, then fell by 1.33% to $74000.0 in 2023, then grew by 1.35% to $75000.0 in 2024, then decreased by 8.0% to $69000.0 in 2025.
  • Business Quant data shows Amortization of Deferred Charges for TMCI at $69000.0 in Q4 2025, $75000.0 in Q3 2025, and $74000.0 in Q2 2025.